ADB-5'Br-PINACA explained

Iupac Name:N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-5-bromoindazole-3-carboxamide
Width:200px
Legal De:NpSG
Legal Uk:Class B
Pubchem:168310461
Chemspiderid:115285280
Smiles:NC(=O)[C@@H](NC(=O)c1nn(CCCCC)c2ccc(Br)cc21)C(C)(C)C
C:19
H:27
Br:1
N:4
O:2
Stdinchi:1S/C19H27BrN4O2/c1-5-6-7-10-24-14-9-8-12(20)11-13(14)15(23-24)18(26)22-16(17(21)25)19(2,3)4/h8-9,11,16H,5-7,10H2,1-4H3,(H2,21,25)(H,22,26)/t16-/m1/s1
Stdinchikey:OUVRBTCXLMBRLT-MRXNPFEDSA-N

ADB-5'Br-PINACA (5'-Br-ADB-PINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Abu Dhabi in September 2022,[1] but has subsequently been found in the US and Europe.[2] While formal pharmacology studies have not yet been carried out, ADB-5'Br-PINACA is believed to be a highly potent synthetic cannabinoid with similar potency to compounds such as MDMB-FUBINACA and 5F-ADB which have been responsible for numerous fatal and non-fatal drug overdoses, consistent with previously reported compounds from the patent literature showing bromination of the indazole ring at the 5-, 6- or 7- positions to increase potency over the unsubstituted analogues.[3] ADB-5'Br-PINACA is the 5'-bromo analog of ADB-PINACA.

Synthesis

ADB-5'Br-PINACA can be synthesized from a "half finished" synthesis precursor known as ADB-5-Br-INACA, related to MDMB-5Br-INACA.[4]

Legality

ADB-5'Br-PINACA is not specifically scheduled in the United States at the federal level as of October 20, 2023 but may be considered illegal under the federal analogue act if intended for consumption as a structural analog of the Schedule I cannabinoid ADB-PINACA.

See also

Notes and References

  1. Web site: The ADJD's Centre of Forensic and Digital Sciences Discovers a New Synthetic Cannabinoid Substance. . Emirates 24/7 . 15 May 2023 .
  2. Web site: ADB-5'Br-PINACA Monograph. . The Center For Forensic Science Research & Education . April 2023 .
  3. WO . 2009106982 . Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK . Indazole Derivatives . Pfizer Inc. . 3 September 2009 .
  4. Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, McKenzie C, Gréen H, Stove CP . 6 . In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs . Drug Testing and Analysis . October 2023 . 37903509 . 10.1002/dta.3592 . 264671035 .